Scynexis Inc (SCYX)

Oct 06, 2026

SCYNEXIS completes phase 1 study of SCY-770 for kidney disease - Investing.com Nigeria

Oct 06, 2026

Oct 06, 2026

SCYNEXIS completes phase 1 study of SCY-770 for kidney disease - Investing.com

Oct 06, 2026

Oct 06, 2026

SCYNEXIS (SCYX) Completes Phase 1 Trial for SCY-770 Targeting AD - GuruFocus

Oct 06, 2026

Oct 06, 2026

SCYNEXIS completes phase 1 study of SCY-770 for kidney disease - Investing.com Canada

Oct 06, 2026

Oct 06, 2026

SCYNEXIS Announces Positive Phase 1 Results for SCY-770 in ADPKD, Supports Planned Phase 2 Study in Q4 2026 - Quiver Quantitative

Oct 06, 2026

Oct 06, 2026

SCYNEXIS Announces Positive Phase 1 Results for SCY-770 in ADPKD, Supports Planned Phase 2 Study in Q4 2026 - Quiver Quantitative

Oct 06, 2026

Oct 06, 2026

An experimental kidney disease drug was well tolerated in 25 healthy adults - Stock Titan

Oct 06, 2026

Oct 06, 2026

SCYNEXIS (NasdaqCM:SCYX) Stock Forecast & Analyst Predictions - Simply Wall Street

Oct 06, 2026

Oct 02, 2026

Stock splits calendar for: - Yahoo Finance UK

Oct 02, 2026

Sep 30, 2026

Scynexis secures up to USD 214m in BARDA funding for antifungal SCY-247 - AllSci

Sep 30, 2026

Sep 30, 2026

Scynexis wins BARDA contract worth up to $214 million for antifungal SCY-247 - The Pharma Letter

Sep 30, 2026

Sep 28, 2026

SCYNEXIS Secures BARDA Funding for Antifungal Pipeline - TipRanks

Sep 28, 2026

Sep 28, 2026

SCYNEXIS Inc. (SCYX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com

Sep 28, 2026

Sep 28, 2026

SCYNEXIS Inc. (SCYX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com

Sep 28, 2026

Sep 28, 2026

SCYNEXIS Inc. (SCYX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Sep 28, 2026

Sep 28, 2026

Scynexis stock surges on $214M BARDA contract for SCY-247 - Yahoo Finance

Sep 28, 2026

Sep 28, 2026

Scynexis stock surges on $214M BARDA contract for SCY-247 - Investing.com

Sep 28, 2026

Sep 28, 2026

SCYX Stock Draws Trader Focus As New CFO And ADPKD Pivot Take Shape - timothysykes.com

Sep 28, 2026

Sep 28, 2026

SCYX Stock Draws Traders As Leadership And Kidney Pivot Advance - StocksToTrade

Sep 28, 2026

Sep 28, 2026

SCYNEXIS Wins BARDA Contract Worth Up to $214 Million for SCY-247 - citybiz

Sep 28, 2026

Sep 28, 2026

SCYNEXIS secures BARDA contract for antifungal development - Investing.com

Sep 28, 2026

Sep 28, 2026

Scynexis Shares Rise 13.9% After BARDA Awards SCY-247 Development Contract - Yahoo Finance

Sep 28, 2026

Sep 28, 2026

Why is Scynexis stock surging today? By Investing.com - Investing.com South Africa

Sep 28, 2026

Sep 28, 2026

Why is Scynexis stock surging today? By Investing.com - Investing.com Canada

Sep 28, 2026

Sep 28, 2026

Why is Scynexis stock surging today? - Investing.com

Sep 28, 2026

Sep 28, 2026

SCYNEXIS secures BARDA contract for antifungal development By Investing.com - Investing.com India

Sep 28, 2026

Sep 28, 2026

A U.S. health agency could provide up to about $214 million to develop an antifungal treatment if all options are exercised. - Stock Titan

Sep 28, 2026

Sep 27, 2026

Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch - TradingView

Sep 27, 2026

Sep 23, 2026

SCYNEXIS, Inc. (SCYX) Stock Price, News, Quote & History - Yahoo! Finance Canada

Sep 23, 2026

Sep 22, 2026

SCYNEXIS, Inc. Announces Appointment of Steven K. Burke, M.D. to its Board of Directors, Effective September 18, 2026 - marketscreener.com

Sep 22, 2026

Sep 22, 2026

Scynexis appoints Steven Burke to board of directors - Investing.com

Sep 22, 2026

Sep 22, 2026

Scynexis (NASDAQ: SCYX) adds kidney drug specialist to its board - Stock Titan

Sep 22, 2026

Sep 22, 2026

SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors - manilatimes.net

Sep 22, 2026

Sep 22, 2026

SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors - marketscreener.com

Sep 22, 2026

Sep 22, 2026

SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors - Stock Titan

Sep 22, 2026

Sep 22, 2026

Press Release: SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to Its Board of Directors - Moomoo

Sep 22, 2026

Sep 21, 2026

SCYXPhase II ADPKD Catalyst Will Define Long-Term Potential For This Orphan Kidney Therapy - Simply Wall Street

Sep 21, 2026

Sep 21, 2026

SCYNEXIS (Nasdaq:SCYX)Stock Analysis - Simply Wall Street

Sep 21, 2026

Sep 15, 2026

Scynexis appoints Todd Minga as senior VP of R&D - Investing.com

Sep 15, 2026

Sep 15, 2026

A kidney specialist joins SCYNEXIS to lead rare-disease research - Stock Titan

Sep 15, 2026

Sep 12, 2026

SCYNEXIS Inc Extraordinary Shareholders Meeting Transcript - GuruFocus

Sep 12, 2026

Sep 11, 2026

SCYNEXIS at Cantor healthcare conference: rare-disease push takes shape By Investing.com - Investing.com South Africa

Sep 11, 2026

Sep 11, 2026

Scynexis (SCYX) awards CFO 100,000 stock options vesting over 4 years - Stock Titan

Sep 11, 2026

Sep 11, 2026

New Scynexis (SCYX) CFO reports no company shares - Stock Titan

Sep 11, 2026

Sep 11, 2026

SCYNEXIS at Cantor healthcare conference: rare-disease push takes shape By Investing.com - Investing.com Nigeria

Sep 11, 2026

Sep 11, 2026

SCYNEXIS INC (NASDAQ: SCYX) Appoints Sanjay Subramanian as CFO with $500,000 Annual Salary - Kalkine Media

Sep 11, 2026

Sep 11, 2026

SCYX: Phase II trial of SCY-770 for ADPKD to launch by year-end, targeting major unmet need - TradingView

Sep 11, 2026

Sep 11, 2026

SCYX: Phase II trial of SCY-770 for ADPKD to launch by year-end, targeting major unmet need - TradingView

Sep 11, 2026

Sep 11, 2026

SCYNEXIS at Cantor healthcare conference: rare-disease push takes shape - Investing.com

Sep 11, 2026

Sep 11, 2026

SCYNEXIS at Cantor healthcare conference: rare-disease push takes shape By Investing.com - Investing.com India

Sep 11, 2026